Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Autor: Hatsukami DK; Department of Psychiatry, University of Minnesota Tobacco Use Programs, Minneapolis, Minnesota, USA. hatsu001@umn.edu, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, Fahim RE, Kessler PD, Niknian M, Kalnik MW, Rennard SI

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2011 Mar; Vol. 89 (3), pp. 392-9. Date of Electronic Publication: 2011 Jan 26.